|
Patent landscape, scope, and claims: |
United States Drug Patent 6,503,884: Scope, Claims, and Landscape Analysis
United States Patent 6,503,884, titled "Substituted 2-amino-imidazo[1,2-a]pyridines," was granted on January 7, 2003, to Merck & Co., Inc. The patent claims a class of chemical compounds, their preparation, and their use in treating various medical conditions, primarily those associated with excessive or inappropriate signal transduction by receptors belonging to the G-protein coupled receptor (GPCR) superfamily. Specifically, the compounds are described as antagonists of the vasopressin V2 receptor.
What Is the Core Invention Claimed by Patent 6,503,884?
The central invention of patent 6,503,884 resides in the composition of matter claims for a specific class of substituted 2-amino-imidazo[1,2-a]pyridine derivatives. These compounds are defined by a core heterocyclic ring system with various substituents at specific positions. The patent also claims pharmaceutical compositions containing these compounds and methods of using them.
The key structural features of the claimed compounds are:
- A 2-amino-imidazo[1,2-a]pyridine core structure.
- Substituents denoted as R1, R2, R3, R4, and R5, each defining a specific range of chemical groups (e.g., hydrogen, alkyl, aryl, heteroaryl, halogens, etc.).
- Specific linking groups or direct attachments for these substituents to the core structure.
The patent enumerates numerous examples of specific compounds falling within these defined generic structures, illustrating the breadth of the claimed chemical space.
What Medical Conditions Are Targeted by the Patented Compounds?
The compounds disclosed and claimed in US Patent 6,503,884 are primarily indicated for treating conditions mediated by the vasopressin V2 receptor. These conditions include:
- Hyponatremia: Specifically, euvolemic and hypervolemic hyponatremia. The V2 receptor plays a crucial role in water reabsorption in the kidneys. Antagonizing this receptor reduces water reabsorption, leading to increased free water excretion and a subsequent increase in serum sodium concentration.
- Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH): SIADH is characterized by excessive secretion of ADH, leading to water retention and dilutional hyponatremia. V2 receptor antagonists help to correct the water imbalance.
- Congestive Heart Failure (CHF): In CHF, the body often retains excess fluid due to dysregulation of hormones, including ADH. V2 receptor antagonists can aid in managing fluid overload.
- Liver Cirrhosis with Ascites: Similar to CHF, fluid retention is a significant complication of liver cirrhosis.
- Pulmonary Fibrosis: The patent suggests potential applications in this condition, although the V2 receptor's role is less established than in fluid balance disorders.
- Other Disorders Associated with Excessive GPCR Signal Transduction: The patent broadly claims utility in conditions where hyperactivity of GPCRs, particularly those involved in water homeostasis, is a contributing factor.
The mechanism of action centers on blocking the binding of endogenous vasopressin (antidiuretic hormone or ADH) to the V2 receptors located in the collecting ducts of the kidneys. This blockade inhibits the downstream signaling pathways that lead to aquaporin-2 (AQP2) channel insertion into the apical membrane of principal cells, thereby reducing water reabsorption.
What Is the Prior Art Landscape for Vasopressin Receptor Antagonists at the Time of Filing?
The filing date of US Patent 6,503,884 is October 13, 2000. At this time, the field of vasopressin receptor antagonists was an active area of pharmaceutical research. Prior art efforts had identified various chemical classes as potential V2 receptor antagonists.
Key prior art considerations would have included:
- Non-peptide V2 Antagonists: Several research groups and pharmaceutical companies were developing small molecule, non-peptide antagonists. This was a significant departure from earlier peptide-based antagonists which suffered from poor oral bioavailability and short half-lives.
- Established V2 Antagonist Structures: Literature and existing patents would have disclosed various heterocyclic scaffolds and substituted aromatic compounds as V2 antagonists. For example, benzodiazepine derivatives and other nitrogen-containing heterocycles had been explored.
- Tolvaptan (OPC-41061): Otsuka Pharmaceutical's tolvaptan, a selective V2 receptor antagonist, was in late-stage clinical development around the turn of the millennium and had demonstrated efficacy in treating hyponatremia. This represented a significant benchmark in the field.
- Receptor Selectivity: A critical aspect of prior art was the pursuit of selectivity for the V2 receptor over other vasopressin receptors (V1a and V1b). Compounds lacking selectivity could lead to unwanted side effects, such as changes in blood pressure (V1a antagonism) or hormonal effects (V1b antagonism).
The patentability of US 6,503,884 would have depended on demonstrating that the claimed imidazo[1,2-a]pyridine compounds possessed novel structural features, exhibited unexpected advantageous properties (e.g., potency, selectivity, pharmacokinetic profile), or offered a distinct advantage over existing approaches.
What Are the Key Claims of Patent 6,503,884?
The patent's claims are structured to cover the core invention broadly and then narrow down to specific embodiments.
Claim 1 (Independent): This is typically the broadest claim covering the general chemical structure. It claims a compound of Formula I:
R3
|
/\
/ \
/ \
N------C ---- N - R2
| | |
C------C C
/ \ / \ / \
C---C--N---C--C---C
| | |
R4 R5 R1
or a pharmaceutically acceptable salt thereof, wherein:
- R1 is selected from the group consisting of hydrogen, alkyl, acyl, carbamoyl, aryl, heteroaryl, and substituted aryl and substituted heteroaryl;
- R2 is selected from the group consisting of hydrogen, alkyl, acyl, carbamoyl, aryl, heteroaryl, and substituted aryl and substituted heteroaryl;
- R3 is selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, haloalkoxy, aryl, heteroaryl, and substituted aryl and substituted heteroaryl;
- R4 is selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, haloalkoxy, aryl, heteroaryl, and substituted aryl and substituted heteroaryl;
- R5 is selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, haloalkoxy, aryl, heteroaryl, and substituted aryl and substituted heteroaryl;
with the proviso that at least one of R1, R2, R3, R4, and R5 is other than hydrogen.
This claim defines the generic class of compounds, allowing for significant structural variation within the defined parameters. The crucial element is the 2-amino-imidazo[1,2-a]pyridine core and the substituents at various positions.
Dependent Claims (e.g., Claims 2-40): These claims narrow the scope of Claim 1 by specifying particular sub-groups for the substituents R1-R5, or by claiming specific examples of compounds detailed in the patent. For instance, a dependent claim might specify that R1 is a particular substituted phenyl group or that R2 is an alkyl chain of a certain length. These claims provide fallback positions and protect specific, well-characterized embodiments.
Claim 41 (Method of Treatment): This claim covers the method of treating conditions mediated by the vasopressin V2 receptor by administering a therapeutically effective amount of a compound of Formula I. This claim is directed to the use of the patented compounds.
Claim 42 (Pharmaceutical Composition): This claim covers a pharmaceutical composition comprising a compound of Formula I and a pharmaceutically acceptable carrier.
The claims are designed to provide broad protection for the chemical space around the novel imidazo[1,2-a]pyridine scaffold while also securing protection for specific, tested embodiments and their therapeutic applications.
What Is the Patent Landscape for Vasopressin V2 Receptor Antagonists Post-2003?
Following the issuance of US Patent 6,503,884, the landscape for V2 receptor antagonists continued to evolve, characterized by:
- Further Development of Existing Compounds: Merck, the assignee of 6,503,884, has developed and marketed tolvaptan (which is distinct from the compounds claimed in 6,503,884 but belongs to the broader class of V2 antagonists). Other companies also pursued their own pipelines.
- Emergence of Approved Therapies: The first selective V2 receptor antagonist approved for marketing was tolvaptan (Samsca® by Otsuka), approved by the FDA in 2009 for treating clinically significant hypernatremia in patients with certain medical conditions. More recently, lixivaptan and satavaptan have also been explored and some have received approval in specific regions or for specific indications.
- Patent Expirations and Generics: As patents for early V2 antagonists approach or pass their expiration dates, the market is opening for generic versions, increasing competition. For example, the patent for tolvaptan has seen generic entry.
- New Chemical Scaffolds: Research has continued to identify novel chemical scaffolds with V2 antagonist activity, seeking improved efficacy, safety profiles, or patentability. This includes exploring different heterocyclic systems and substituent patterns.
- Focus on Specific Indications: While hyponatremia remains a primary target, research has expanded to other areas where V2 receptor modulation may be beneficial, such as autosomal dominant polycystic kidney disease (ADPKD) and other fibrotic conditions.
- Litigation and Licensing: The high commercial value of effective treatments for conditions like hyponatremia has led to patent litigation and licensing agreements between pharmaceutical companies.
The existence of patent 6,503,884 contributed to this landscape by establishing a protected area of chemical innovation. Companies seeking to develop V2 antagonists would have had to navigate around its claims, either by developing compounds that did not fall within its scope or by obtaining licenses.
What Are the Commercial Implications of Patent 6,503,884?
The commercial implications of US Patent 6,503,884 are tied to the therapeutic potential of the claimed compounds.
- Market Entry Barrier: For any company seeking to develop and market compounds falling within the scope of this patent, it presented a significant barrier to entry. Direct infringement would not be possible without a license from Merck.
- Licensing Opportunities: If Merck identified specific compounds from its patent that showed particularly strong therapeutic promise, it could license these compounds to other companies for further development or co-promotion.
- Pipeline Contribution: The patent represents a portion of Merck's intellectual property in the cardiovascular and renal therapeutic areas. Its value is realized if and when compounds derived from it successfully navigate clinical development and reach the market.
- Freedom to Operate (FTO) Analysis: For other pharmaceutical companies developing V2 antagonists, this patent would be a critical consideration in their FTO analyses. They would need to ensure their candidate compounds did not infringe on any of the claims.
- Valuation: The patent's existence and scope influence the valuation of Merck's R&D assets and potential future revenue streams associated with V2 receptor antagonism.
Given that US Patent 6,503,884 was granted in 2003, its term would have expired in 2023. Therefore, its exclusivity-granting function is now concluded in the United States. However, its influence on the development trajectory of V2 antagonists and its role in defining the patent landscape during its term are significant.
Key Takeaways
- US Patent 6,503,884 claims a broad class of substituted 2-amino-imidazo[1,2-a]pyridine compounds and their use as vasopressin V2 receptor antagonists.
- The patent targets therapeutic applications including hyponatremia, SIADH, and congestive heart failure, by reducing water reabsorption in the kidneys.
- The patent was filed in 2000, during a period of active research into non-peptide V2 antagonists, with Otsuka's tolvaptan nearing market approval.
- The claims are structured to cover a wide range of chemical modifications to the core imidazo[1,2-a]pyridine scaffold, providing broad protection for Merck & Co., Inc.
- The patent expired in 2023, removing its exclusivity barrier.
FAQs
-
What is the expiration date of US Patent 6,503,884?
US Patent 6,503,884 expired on January 7, 2023, marking the end of its 20-year term from the filing date.
-
Are the compounds claimed in this patent still under exclusivity?
No, as of January 7, 2023, the patent term has expired, and the compounds falling directly within its claims are no longer under patent exclusivity in the United States.
-
Can other companies now develop and sell drugs based on the exact chemical structures claimed in patent 6,503,884?
Yes, any company can now develop and sell drugs based on the exact chemical structures claimed in patent 6,503,884 without infringing on this specific patent. However, other patents covering improved formulations, specific medical uses, or manufacturing processes might still be in effect.
-
Does this patent cover tolvaptan?
No, US Patent 6,503,884 does not cover tolvaptan. Tolvaptan is a selective V2 receptor antagonist developed by Otsuka Pharmaceutical and is covered by different patent families. While both target the V2 receptor, the chemical structures and patent claims are distinct.
-
What is the primary medical indication for the compounds described in this patent?
The primary medical indication described for the compounds in US Patent 6,503,884 is the treatment of conditions mediated by the vasopressin V2 receptor, such as hyponatremia, SIADH, and congestive heart failure, by antagonizing V2 receptor activity to promote free water excretion.
Citations
[1] United States Patent 6,503,884. (2003). Substituted 2-amino-imidazo[1,2-a]pyridines. Retrieved from United States Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
